1. Catalog
  2. Nodes
  3. a(CHEBI:varenicline)

a(CHEBI:varenicline)

Equivalencies: 0 | Classes: 0 | Children: 0 | Explore

Entity

Name
varenicline
Namespace
chebi
Namespace Version
20180906
Namespace URL
https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns

Appears in Networks 2

Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system v1.0.0

This document contains the curation of the review article Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system by Taly et al. 2009

Discriminative Stimulus Properties of S(−)-Nicotine: “A Drug for All Seasons v1.0.0

In-Edges 0

Out-Edges 5

a(CHEBI:varenicline) increases path(MESH:"Smoking Cessation") View Subject | View Object

varenicline (Chantix/Champix; Pfizer), the most recently approved drug for smoking cessation which is now on the market, is a partial agonist at alpha4beta2 nAChRs, and a full agonist at alpha7 nAChRs (ReF. 200). PubMed:19721446

Appears in Networks:
Annotations
Text Location
Review

a(CHEBI:varenicline) increases act(p(HBP:"alpha-4 beta-2 nAChR")) View Subject | View Object

varenicline (Chantix/Champix; Pfizer), the most recently approved drug for smoking cessation which is now on the market, is a partial agonist at alpha4beta2 nAChRs, and a full agonist at alpha7 nAChRs (ReF. 200). PubMed:19721446

Appears in Networks:
Annotations
Text Location
Review

a(CHEBI:varenicline) increases act(p(HGNC:CHRNA7)) View Subject | View Object

varenicline (Chantix/Champix; Pfizer), the most recently approved drug for smoking cessation which is now on the market, is a partial agonist at alpha4beta2 nAChRs, and a full agonist at alpha7 nAChRs (ReF. 200). PubMed:19721446

Appears in Networks:
Annotations
Text Location
Review

a(CHEBI:varenicline) increases act(a(MESH:"nicotinic receptor alpha4beta2")) View Subject | View Object

Varenicline (Chantix®; Fig. 4) is prescribed as an adjunct medication in smoking cessation therapy and is thought to exert its effects as a partial agonist at α4β2 nAChRs and as a full agonist at α7 nAChRs [211, 212]. PubMed:28391535

Appears in Networks:

a(CHEBI:varenicline) increases act(a(MESH:"alpha7 Nicotinic Acetylcholine Receptor")) View Subject | View Object

Varenicline (Chantix®; Fig. 4) is prescribed as an adjunct medication in smoking cessation therapy and is thought to exert its effects as a partial agonist at α4β2 nAChRs and as a full agonist at α7 nAChRs [211, 212]. PubMed:28391535

Appears in Networks:

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.